Anti-inflammatory immunoglobulin production

"Anti-inflammatory immunoglobulin production" is **not a specific molecular target** such as a receptor, enzyme, or transporter. Instead, it refers to the process by which certain forms or modifications of immunoglobulins—particularly intravenous immunoglobulin (IVIg) preparations enriched for sialylated IgG—exert broad **anti-inflammatory effects** in vivo. These effects are mediated through complex interactions involving the glycosylation state of the IgG Fc region and its recognition by specific lectin receptors such as SIGN-R1 in mice and DC-SIGN in humans. This interaction leads to downstream upregulation of inhibitory FcγRIIB on effector macrophages and modulation of inflammatory responses through changes in cytokine profiles—including increased IL‑10 and TGF‑β secretion—and inhibition or regulation at multiple points within both innate and adaptive immunity.[1][3][5] The term does not denote a single gene product or druggable protein but rather describes an **immunomodulatory mechanism** relevant for treating autoimmune diseases and inflammatory conditions. Because "anti-inflammatory immunoglobulin production" is not itself a discrete molecular entity but rather describes an outcome/process involving multiple molecules (immunoglobulins), cell types, post-translational modifications (such as sialylation), and signaling pathways, it should not be considered a canonical therapeutic target per se. Therefore: > There is something incorrect about this entry—it does not correspond to an individual molecule/receptor/protein that can be directly targeted by drugs but instead refers to an overall biological process. References supporting these statements include mechanistic studies showing that only certain glycoforms (e.g., α2,6-sialylated IgG) mediate anti-inflammatory activity via defined cellular pathways involving lectin receptors like SIGN-R1/DC-SIGN leading to upregulation/inhibition cascades.[1][3] The broader literature also emphasizes that IVIg's mechanisms are multifaceted—including blockade/modulation at several immune checkpoints—and do not map onto one unique molecular target.[5][8]

Other names

Anti-inflammatory immunoglobulin productionImmunoglobulin-mediated anti-inflammatory activityIVIg anti-inflammatory effect

Upregulation of inhibitory FcγRIIB on effector macrophages via sialylated IgG Fc interaction with SIGN-R1/DC-SIGN receptors - Modulation and suppression of pro-inflammatory cytokines; induction of anti-inflammatory cytokines such as IL‑10 and TGF‑β from monocytes/macrophages